Yen Near 40-Year Low as USD/JPY Approaches Key 162 Level, Raising Intervention Concerns 
Malaysia Central Bank Moves to Support Ringgit Amid Foreign Fund Outflows 
White House Seeks $87.6 Billion Emergency Funding for Iran War, Farmers, and Ebola Response 
Wall Street Slides as AI Stocks Tumble Following South Korea Tech Sell-Off 
Asian Stocks Slip as Oil Rebounds Amid Fed Rate Hike Fears 
Singapore Inflation Stays Muted in May as Core CPI Misses Forecasts Ahead of MAS Review 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
South Korea Remains MSCI Emerging Market Despite Reform Progress 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Asian Stocks Slide as AI Rally Pauses, South Korean Chipmakers Lead Regional Decline 
Australia Jobs Growth Strengthens Rate Hike Outlook 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Abbott Nutrition said last weekend that it had reopened its Sturgis, Michigan plant to resume the production of baby formula. The company hopes that the nationwide shortage of milk will be addressed once it begins the normal production once again.
Abbott Nutrition was able to open its production facility in Michigan after the U.S. Food and Drug Administration (USFDA) had given it the go-ahead to do so. The permit was granted by the agency after the company met the initial requirements as part of a May 16 consent decree.
According to CNBC, Abbott Nutrition will now restart the production of its EleCare baby formula that has been formulated for children who have difficulties digesting other products. The company will also manufacture its other specialty milk and metabolic formulas for infants.
As the company is now able to begin production again, it is hoping to release the first batch of EleCare milk products by June 20. Currently, Abbott is still working to comply with the guidelines set for the resumption of production for its Similac milk line and other infant formulas.
“We understand the urgent need for formula and our top priority is getting high-quality, safe formula into the hands of families across America,” Abbott’s spokesman said in a statement. “We will ramp production as quickly as we can while meeting all requirements.“
It was noted that the issue with the supply of baby formula began in the early stage of the COVID-19 pandemic. However, the situation got worse when Abbott Nutrition’s production facility in Michigan was ordered to close due to contamination. The plant was shut down in February following reports of illnesses in babies after consuming the company-made milk formulas, and two infants have died.
“The FDA is continuing to work diligently to ensure the safe resumption of production of infant formula at Abbott Nutrition’s Sturgis, Michigan, facility,” the USFDA commented with regards to Abbot’s plant reopening. “The agency expects that the measures and steps it is taking, and the potential for Abbott Nutrition’s Sturgis, Michigan, facility, to safely resume production in the near-term, will mean more and more infant formula is either on the way to or already on store shelves moving forward.”
